GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-302-30	30 TABLET in 1 BOTTLE (64764-302-30)	2006-07-28
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-302-90	90 TABLET in 1 BOTTLE (64764-302-90)	2006-07-28
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925	NDA	Takeda Pharmaceuticals America, Inc.	64764-304-30	30 TABLET in 1 BOTTLE (64764-304-30)	2006-07-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies primary suppliers for glimepiride and pioglitazone hydrochloride, detailing their manufacturing capabilities, market presence, and relevant patent expirations. The information is critical for pharmaceutical companies assessing supply chain resilience, competitive positioning, and potential generic entry strategies.

Who Are the Leading Manufacturers of Glimepiride and Pioglitazone Hydrochloride?

The global supply of glimepiride and pioglitazone hydrochloride is concentrated among a select group of manufacturers, primarily based in India and China, which have emerged as dominant players in Active Pharmaceutical Ingredient (API) production. These suppliers offer varying scales of production, quality certifications, and regulatory compliance, catering to diverse market needs.

Glimepiride Suppliers

Glimepiride, a sulfonylurea antidiabetic drug, has a well-established manufacturing base. Key suppliers include:

Laurus Labs: A significant Indian API manufacturer with a broad portfolio, including glimepiride. The company holds US FDA, EDQM, and other international regulatory approvals. Laurus Labs' production capacity and robust quality systems position it as a primary supplier for regulated markets.
Aurobindo Pharma: Another major Indian pharmaceutical company that manufactures and markets a wide range of APIs. Aurobindo is a key supplier of glimepiride, with facilities compliant with global regulatory standards.
Divi's Laboratories: Renowned for its large-scale API production, Divi's Laboratories is a prominent producer of glimepiride. The company operates multiple cGMP-compliant manufacturing sites in India and is a consistent supplier to global pharmaceutical firms.
Sun Pharmaceutical Industries: As one of the largest pharmaceutical companies globally, Sun Pharma produces glimepiride API through its API manufacturing divisions. Its extensive reach and regulatory expertise support its role as a substantial supplier.
Hetero Drugs: A leading Indian pharmaceutical company with a strong API manufacturing presence. Hetero supplies glimepiride and has a comprehensive regulatory dossier for its product.

Pioglitazone Hydrochloride Suppliers

Pioglitazone hydrochloride, a thiazolidinedione antidiabetic drug, also has a concentrated supply chain. Key manufacturers include:

Intas Pharmaceuticals: An Indian multinational pharmaceutical company with substantial API manufacturing capabilities. Intas is a significant supplier of pioglitazone hydrochloride, holding necessary regulatory approvals.
Dr. Reddy's Laboratories: A global pharmaceutical company with a strong API business. Dr. Reddy's manufactures pioglitazone hydrochloride, leveraging its established manufacturing infrastructure and quality control processes.
Zydus Cadila: This Indian pharmaceutical group has a dedicated API manufacturing arm that produces pioglitazone hydrochloride. The company focuses on quality and compliance for its API offerings.
Emcure Pharmaceuticals: A vertically integrated pharmaceutical company that manufactures pioglitazone hydrochloride API. Emcure has a presence in both domestic and international markets for its APIs.
Novartis (through Sandoz): While primarily known as an innovator, Novartis's generics division, Sandoz, may also be involved in the supply of pioglitazone hydrochloride, particularly in certain markets or through established supply agreements. However, the primary API manufacturing for the broader market is dominated by Indian and Chinese firms.

What Are the Key Patent Expirations for Glimepiride and Pioglitazone Hydrochloride?

The patent landscape for both glimepiride and pioglitazone hydrochloride is characterized by expired core patents, paving the way for generic competition. Understanding these expirations is crucial for market entry strategies for generic manufacturers and for innovator companies to manage post-patent life cycles.

Glimepiride Patent Expirations

The primary patents protecting glimepiride have long since expired, allowing for widespread generic production.

Composition of Matter Patent: The original patents covering the glimepiride molecule expired decades ago. For example, U.S. Patent 4,215,141, assigned to Hoechst AG (now part of Sanofi), which claimed the glimepiride compound, expired in the late 1990s or early 2000s depending on extensions.
Formulation and Method of Use Patents: While core composition of matter patents are expired, secondary patents related to specific formulations, polymorphs, or methods of treatment might have existed. However, these generally have also expired or have been successfully challenged by generic manufacturers.
Market Exclusivity: For branded glimepiride products (e.g., Amaryl), regulatory exclusivity periods have also concluded, enabling generic market entry.

Timeline Overview:

Early 2000s: Widespread generic availability in major markets like the U.S. and Europe.
Present: Glimepiride is a fully genericized drug with numerous API suppliers and finished dosage form manufacturers.

Pioglitazone Hydrochloride Patent Expirations

Similar to glimepiride, pioglitazone hydrochloride's patent protection has largely concluded, leading to a mature generic market.

Composition of Matter Patent: The fundamental patents for pioglitazone hydrochloride expired. For instance, U.S. Patent 4,687,777, originally assigned to Sankyo Company, Limited (now Daiichi Sankyo), which covered pioglitazone, expired in the mid-2000s. Patent term extensions and adjustments could have slightly altered these dates, but the core exclusivity is long gone.
Formulation and Polymorph Patents: Secondary patents for specific pioglitazone hydrochloride formulations or crystalline forms were subject to litigation and challenges. For example, patents related to specific polymorphs were a point of contention in litigation involving generic competitors and the innovator. These patents have either expired or been invalidated for many markets.
Market Exclusivity: Branded pioglitazone hydrochloride products, such as Actos, have also seen their market exclusivity expire, allowing generic versions to enter and capture significant market share.

Timeline Overview:

Mid to Late 2000s: Initial generic entries into major markets following patent expirations.
Early 2010s onwards: Significant market penetration by generic pioglitazone hydrochloride manufacturers.
Present: Pioglitazone hydrochloride is a widely available generic medication.

What Are the Regulatory Considerations for API Suppliers?

Suppliers of glimepiride and pioglitazone hydrochloride API must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy. Compliance is non-negotiable for market access in regulated territories.

Key Regulatory Bodies and Standards:

U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with Current Good Manufacturing Practices (cGMP). FDA inspections and facility audits are critical for obtaining or maintaining drug master file (DMF) acceptance.
European Medicines Agency (EMA) / EDQM: For the European market, suppliers must meet European Pharmacopoeia (Ph. Eur.) standards and adhere to cGMP guidelines. Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEPs) issued by the EDQM are often required.
Other National Regulatory Authorities: Agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and others have their own specific requirements, often aligning with ICH guidelines.
International Council for Harmonisation (ICH): ICH guidelines, particularly ICH Q7 for API manufacturing, provide a framework for global quality standards.

Common Regulatory Submissions:

Drug Master Files (DMFs): Suppliers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, facilities, quality control, and stability. Pharmaceutical companies reference these DMFs in their own drug applications.
Active Substance Master Files (ASMFs): The European equivalent of DMFs.
Written Confirmations: For APIs exported to the EU, a "Written Confirmation" from the exporting country's competent authority is required to attest that the manufacturing standards are equivalent to EU GMP.

Quality Certifications and Audits:

cGMP Compliance: This is the foundational requirement. Regular audits by customers and regulatory bodies verify ongoing compliance.
ISO Certifications: While not directly pharmaceutical regulatory requirements, ISO certifications (e.g., ISO 9001) can indicate a robust quality management system.
Customer Audits: Pharmaceutical companies routinely audit their API suppliers to ensure they meet internal quality standards and regulatory expectations.

What Is the Competitive Landscape for Generic Glimepiride and Pioglitazone Hydrochloride?

The generic market for both glimepiride and pioglitazone hydrochloride is highly competitive, characterized by price erosion due to a large number of manufacturers and established generic players.

Glimepiride Market Dynamics:

Numerous Generic Manufacturers: A significant number of companies worldwide produce generic glimepiride finished dosage forms.
API Price Sensitivity: The availability of multiple high-quality API suppliers has led to intense price competition among API manufacturers.
Therapeutic Equivalence: Glimepiride is well-established, and its therapeutic equivalence is widely recognized, facilitating generic substitution.
Market Share: Branded products hold a diminishing market share, with generics dominating prescription volumes.

Pioglitazone Hydrochloride Market Dynamics:

Mature Generic Market: Pioglitazone hydrochloride has been available generically for an extended period, leading to market saturation.
Price Competition: Intense pricing pressure exists for both the API and the finished dosage forms.
Combination Products: Pioglitazone is often formulated in combination with other antidiabetic drugs (e.g., metformin, sitagliptin). The patent status and supply chain for these combination products add further complexity.
Navigating Litigation: Generic companies have historically navigated complex patent litigation surrounding pioglitazone, particularly concerning specific crystalline forms, which can influence market entry timing and exclusivity.

Key Competitive Factors:

API Cost and Availability: Reliable, cost-effective supply of high-quality API is paramount.
Regulatory Dossier Strength: Comprehensive and accepted regulatory filings (DMFs, ANDAs) are crucial for market approval.
Manufacturing Scale and Efficiency: The ability to produce at scale efficiently impacts cost competitiveness.
Quality and Compliance Record: A strong track record of regulatory compliance minimizes supply chain risks.
Supply Chain Security: Robust supply chain management to prevent stockouts or disruptions.

Are There Any Emerging Trends or Future Considerations?

While glimepiride and pioglitazone hydrochloride are mature products, several factors could influence their future supply and market dynamics.

Supply Chain Diversification: Increasing awareness of supply chain vulnerabilities, particularly following global events, may drive pharmaceutical companies to seek diversification of API suppliers, potentially beyond the dominant Indian and Chinese markets.
Quality Standard Harmonization: Continued efforts towards global harmonization of quality standards (e.g., via ICH) will likely reinforce cGMP compliance as a universal requirement.
Focus on Green Chemistry and Sustainability: As environmental regulations tighten, API manufacturers may face increasing pressure to adopt more sustainable manufacturing processes, which could impact production costs and require new investments.
Regulatory Scrutiny on Impurities: Enhanced regulatory focus on impurity profiles (e.g., nitrosamines, elemental impurities) necessitates advanced analytical capabilities and rigorous process control from API manufacturers.
Market Dynamics in Emerging Economies: Growth in healthcare infrastructure and access in emerging markets will continue to drive demand for these essential antidiabetic medications, offering opportunities for suppliers.

Key Takeaways

The global supply of glimepiride and pioglitazone hydrochloride API is concentrated among manufacturers primarily in India and China.
Key suppliers for glimepiride include Laurus Labs, Aurobindo Pharma, Divi's Laboratories, Sun Pharmaceutical Industries, and Hetero Drugs.
Leading pioglitazone hydrochloride API suppliers comprise Intas Pharmaceuticals, Dr. Reddy's Laboratories, Zydus Cadila, and Emcure Pharmaceuticals.
The composition of matter patents for both glimepiride and pioglitazone hydrochloride have expired, leading to robust generic markets.
API suppliers must meet stringent regulatory requirements, including cGMP compliance, and file comprehensive DMFs/ASMFs with global health authorities.
The generic markets for both drugs are highly competitive, driven by price, quality, and regulatory compliance.
Future considerations include supply chain diversification, sustainability initiatives, and evolving regulatory scrutiny on impurities.

Frequently Asked Questions

What is the typical lead time for API orders of glimepiride or pioglitazone hydrochloride from major suppliers? Lead times can vary significantly based on supplier capacity, order volume, and current market demand. Generally, for established products like these, lead times can range from 4 to 12 weeks. However, large, long-term contracts may involve different scheduling. It is advisable to obtain specific quotes and production schedules directly from suppliers.
Are there specific polymorphs of pioglitazone hydrochloride that are still under patent protection in major markets? While the primary composition of matter patent for pioglitazone hydrochloride has expired, patents related to specific crystalline forms (polymorphs) have been a subject of litigation. Pharmaceutical companies should conduct thorough patent landscape analysis for the specific markets they intend to enter, as some secondary patents may still be active or have led to specific market exclusivities for certain polymorphic forms.
What are the primary quality concerns for API suppliers of these drugs? Key quality concerns include ensuring consistent particle size distribution (critical for tablet dissolution), controlling process-related impurities and degradation products, and verifying enantiomeric purity where applicable. For pioglitazone hydrochloride, controlling specific known impurities is crucial.
How do the regulatory requirements differ between supplying to the US and the EU? While both the US FDA and the EU EMA require cGMP compliance, the submission formats differ. The US uses Drug Master Files (DMFs) submitted directly to the FDA, while the EU utilizes Active Substance Master Files (ASMFs) or Certificates of Suitability (CEPs) from the EDQM. Furthermore, the EU requires Written Confirmations for API imports.
What impact does the rise of biosimil competition in other therapeutic areas have on the generic API market for small molecules like glimepiride and pioglitazone hydrochloride? The rise of biosimil competition in biologics does not directly impact the generic API market for small molecules. These are distinct classes of drugs with entirely different manufacturing processes, regulatory pathways, and market dynamics. The competitive pressures for small molecule generics are driven by the expiry of chemical patents and the entry of multiple synthetic API manufacturers.

Citations

[1] U.S. Patent 4,215,141. (1980). Sulfonylurea derivatives. Hoechst AG. [2] U.S. Patent 4,687,777. (1987). Therapeutically active N-(substituted)-aminocarbonyl-2-oxo-piperidine derivatives. Sankyo Company, Limited. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/ [5] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/ [6] European Medicines Agency. (n.d.). Active Substance Master Files (ASMF). Retrieved from https://www.ema.europa.eu/

Suppliers and packagers for generic pharmaceutical drug: GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE